Andy Stadheim

Andy Stadheim has extensive work experience in the biotechnology and pharmaceutical industries. Andy is currently the Vice President at Entrada Therapeutics, where they have been working since 2020. Prior to this role, they served as the Head of Product Development / Antibody Discovery at Entrada Therapeutics from 2020 to 2021.

Before joining Entrada Therapeutics, Andy worked at Novo Nordisk as a Senior Manager of Quality Control from 2017 to 2020. Andy also held the position of Director at Celdara Medical from 2016 to 2017 and Director of Molecular Discovery at Merck from 2012 to 2016.

Andy's early career was spent at GlycoFi, where they held various roles from 2002 to 2012. Andy served as the Director of Strain Development and High Throughput Screening from 2008 to 2012. Prior to that, they were an Associate Director of High Throughput Screening from 2008 to 2008 and Associate Director of Analytical Development from 2006 to 2008. Andy also held the positions of Senior Scientist from 2005 to 2006 and Scientist II from 2003 to 2005. Andy started their career at GlycoFi as a Scientist I and later served as a Postdoc before assuming other roles within the organization.

Andy's work experience spans across various areas including product development, quality control, molecular discovery, and strain development. With their diverse background, they bring a wealth of knowledge and expertise to their current role as Vice President at Entrada Therapeutics.

Andy Stadheim has a strong educational background in the field of pharmacology and biochemistry. Andy completed their undergraduate studies at Virginia Tech from 1991 to 1994, earning a Bachelor of Science degree in Biochemistry. Prior to this, they attended James Madison University in 1990-1991, studying Biology and Chemistry. Andy then pursued their doctoral degree in Pharmacology at Wake Forest University, where they studied from 1994 to 1998. Following their PhD, Andy Stadheim completed a postdoctoral fellowship in Pharmacology/Experimental Therapeutics at Dartmouth College from 1999 to 2002. In 2016, they attended the Harvard Business School Executive Education program as part of the Merck Emerging Leaders Program.